Par Acquisition Of Kali Will Help Boost Product Offerings 50% In Two Years

Par will pay $135 mil. for the New Jersey-based generic drug firm. The combined company will have 37 pending ANDAs, including first-to-file application for generic version of J&J's Ultracet.